Optimal Organ Health

HTLT Liver Support is the most comprehensive liver and organ support product on the market.  Don't just take our word for it.  We let our products speak for themselves!

500mg TUDCA  |  1000mg Inositol  |  700mg Alpha Lipoic Acid 

TUDCA (Tauroursodeoxycholic Acid Sodium)

TUDCA is recognized as one of the most impressive agents for liver support.  TUDCA has been shown to protect the liver, treat cholestasis, rehabilitate the liver when damage has occurred, reduce stress to any cell’s endoplasmic reticulum, reduce insulin resistance, serve as a neuroprotective agent, and decrease cholesterol.*

Inositol

Inositol plays a role in insulin signaling and may improve the body’s sensitivity to insulin in some cases.  Inositol has been shown to help lower triglyceride levels in the blood, increase HDL levels, and help with high blood pressure and blood sugar issues.*

Alpha Lipoic Acid (ALA)

Alpha-lipoic acid is a vitamin-like chemical called an antioxidant.  The antioxidant properties of alpha-lipoic acid have been linked to several benefits, including lower blood sugar levels, reduced inflammation, reduced liver size, slowed skin aging, and improved nerve function.*

Milk Thistle Extract (80%)

Milk Thistle contains silymarin, a group of compounds said to have antioxidant and anti-inflammatory effects. Milk thistle has been found to help detoxify the liver, improve liver function, prevent cholesterol, rebuild liver cells, and remove toxic substances from the liver.*

Choline

Low levels of choline has been shown to accumulate fat in the liver.  Choline has been shown to help in the transport of fat and cholesterol, energy metabolism, and cell/nerve signaling.*

Selenium

Selenium has been shown to help body processes work correctly, as well as increase the action of antioxidants in the body.  Selenium has also been shown to aid in the stimulation of the thyroid.*

Beet Root Extract

Beet root contains antioxidants that help protect the liver, as well as enhance the liver's ability to function.  Beet root has also been shown to lower blood pressure, reduce triglycerides in the blood, and fight fat deposits in the liver.*

Burdock Root Extract

Burdock Root, best when used with Dandelion Extract, is full of antioxidants that are effective at protecting and enhancing the liver.  Burdock Root has also been shown to remove toxins from the blood.  Lastly, Burdock Root has been shown to stimulate the Lymphatic System, the body's way of "draining" and "detoxifying" blood and other cells.*

Dandelion Extract

Dandelion Extract, best when used with Burdock Root, has been shown to help cleanse the liver via reduction of oxidative stress on the liver, allowing the liver to heal.*

Zinc

Zinc plays a vital role in all types of systems in the body.  For organ health in particular, Zinc has been shown to reduce inflammation of the liver and other organs.  Zinc has also been shown to reduce bad cholesterol levels, allowing the liver and other organs to function more efficiently.*

BioPerine

BioPerine as a patented ingredient has claimed increased absorption of Selenium and other nutrients through thermogenesis.  BioPerine has also shown inflammation reducing benefits.* 

Research:

1. Crosignani, A., Battezzati, P. M., Setchell, K. D., Invernizzi, P., Covini, G., Zuin, M., & Podda, M. (1996). Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. Digestive diseases and sciences, 41(4), 809-815.

2. Kars, M., Yang, L., Gregor, M. F., Mohammed, B. S., Pietka, T. A., Finck, B. N., ... & Klein, S. (2010). Tauroursodeoxycholic acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes, 59(8), 1899-1905. 3. Keene, C. D., Rodrigues, C. M., Eich, T., Linehan-Stieers, C., Abt, A., Kren, B. T., ... & Low, W. C. (2001). A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington's disease. Experimental neurology, 171(2), 351-360. 4. Rodrigues, C. M., Solá, S., Silva, R., & Brites, D. (2000). Bilirubin and amyloid-β peptide induce cytochrome c release through mitochondrial membrane permeabilization. Molecular medicine, 6(11), 936. 5. Rodrigues, C. M., Solá, S., Nan, Z., Castro, R. E., Ribeiro, P. S., Low, W. C., & Steer, C. J. (2003). Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proceedings of the National Academy of Sciences, 100(10), 6087-6092.

6. Elia, A. E., Lalli, S., Monsurrò, M. R., Sagnelli, A., Taiello, A. C., Reggiori, B., La Bella, V., Tedeschi, G., & Albanese, A. (2016). Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. European journal of neurology, 23(1), 45–52. https://doi.org/10.1111/ene.12664 7. Kusaczuk M. (2019). Tauroursodeoxycholate-Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives. Cells, 8(12), 1471. https://doi.org/10.3390/cells8121471 8. Paridaens A, Raevens S, Colle I, Bogaerts E, Vandewynckel YP, Verhelst X, Hoorens A, van Grunsven LA, Van Vlierberghe H, Geerts A, Devisscher L. Combination of tauroursodeoxycholic acid and N-acetylcysteine exceeds standard treatment for acetaminophen intoxication. Liver Int. 2017;37:748–756.

9. Rodrigues CM, Sola S, Nan Z, et al. Tauroursodeoxycholic acid reduces apoptosis and protects against neurological injury after acute hemorrhagic stroke in rats. Proc Natl Acad Sci USA. 2003;100:6087–92. 10. Dong, Y., Yang, S., Fu, B., Liu, F., Zhou, S., Ding, H., & Ma, W. (2020). Mechanism of tauroursodeoxycholic acid-mediated neuronal protection after acute spinal cord injury through AKT signaling pathway in rats. International journal of clinical and experimental pathology, 13(9), 2218–2227. 11. Ma, H., Zeng, M., Han, Y., Yan, H., Tang, H., Sheng, J., Hu, H., Cheng, L., Xie, Q., Zhu, Y., Chen, G., Gao, Z., Xie, W., Wang, J., Wu, S., Wang, G., Miao, X., Fu, X., Duan, L., Xu, J., … Jia, J. (2016). A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine, 95(47), e5391. https://doi.org/10.1097/MD.0000000000005391 12. Keene CD, Rodrigues CM, Eich T, Chhabra MS, Steer CJ, Low WC. Tauroursodeoxycholic acid, a bile acid, is neuroprotective in a transgenic animal model of Huntington’s disease. Proc Natl Acad Sci U S A. 2002 Aug 6;99(16):10671-6. doi: 10.1073/pnas.162362299 13. Guo Q, Shi Q, Li H, Liu J, Wu S, Sun H, Zhou B. Glycolipid Metabolism Disorder in the Liver of Obese Mice Is Improved by TUDCA via the Restoration of Defective Hepatic Autophagy. Int J Endocrinol. 2015;2015:687938. doi: 10.1155/2015/687938. Epub 2015 Nov 19. Retraction in: Int J Endocrinol. 2020 Nov 28;2020:2138532 14. Vettorazzi JF, Ribeiro RA, Borck PC, Branco RC, Soriano S, Merino B, Boschero AC, Nadal A, Quesada I, Carneiro EM. The bile acid TUDCA increases glucose-induced insulin secretion via the cAMP/PKA pathway in pancreatic beta cells. Metabolism. 2016 Mar;65(3):54-63. doi: 10.1016/j.metabol.2015.10.021 15. Cha BH, Jung MJ, Moon BK, Kim JS, Ma Y, Arai Y, Noh M, Shin JY, Kim BS, Lee SH. Administration of tauroursodeoxycholic acid enhances osteogenic differentiation of bone marrow-derived mesenchymal stem cells and bone regeneration. Bone. 2016 Feb;83:73-81. doi: 10.1016/j.bone.2015.10.011 16. Gronbeck KR, Rodrigues CM, Mahmoudi J, Bershad EM, Ling G, Bachour SP, Divani AA. Application of tauroursodeoxycholic acid for treatment of neurological and non-neurological diseases: is there a potential for treating traumatic brain injury? Neurocrit Care. 2016;25:153–166. 17. Yanguas-Casás N, Barreda-Manso MA, Nieto-Sampedro M, Romero-Ramírez L. TUDCA: an agonist of the bile acid receptor GPBAR1/TGR5 with anti-inflammatory effects in microglial cells. J Cell Physiol. 2017;232:2231–2245. 18. Dionísio PA, Amaral JD, Ribeiro MF, Lo AC, D’Hooge R, Rodrigues CM. Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol Aging. 2015;36:228–240. 19. Zhang ZM, Chen J, Chen FH, Yu DL, Li R, Lv CL, Wang HS, Li HL, Li J, Cai YF. Tauroursodeoxycholic acid alleviates secondary injury in the spinal cord via up-regulation of CIBZ gene. Cell Stress Chaperones. 2018;23:551–560. 20. Pan XL, Zhao L, Li L, Li AH, Ye J, Yang L, Xu KS, Hou XH. Efficacy and safety of tauroursodeoxycholic acid in the treatment of liver cirrhosis: a double-blind randomized controlled trial. J Huazhong Univ Sci Technolog Med Sci. 2013 Apr;33(2):189-194. doi: 10.1007/s11596-013-1095-x 21. Crosignani A, Budillon G, Cimino L, Del Vecchio Blanco C, Loguercio C, Ideo G, Raimondo G, Stabilini R, Podda M. Tauroursodeoxycholic acid for the treatment of HCV-related chronic hepatitis: a multicenter placebo-controlled study. Hepatogastroenterology. 1998 Sep-Oct;45(23):1624-9. 22. Ma H, Zeng M, Han Y, Yan H, Tang H, Sheng J, Hu H, Cheng L, Xie Q, Zhu Y, Chen G, Gao Z, Xie W, Wang J, Wu S, Wang G, Miao X, Fu X, Duan L, Xu J, Wei L, Shi G, Chen C, Chen M, Ning Q, Yao C, Jia J. A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis. Medicine (Baltimore). 2016 Nov;95(47):e5391. doi: 10.1097/MD.0000000000005391 23. Kars M, Yang L, Gregor MF, Mohammed BS, Pietka TA, Finck BN, Patterson BW, Horton JD, Mittendorfer B, Hotamisligil GS, Klein S. Tauroursodeoxycholic Acid may improve liver and muscle but not adipose tissue insulin sensitivity in obese men and women. Diabetes. 2010 Aug;59(8):1899-905. doi: 10.2337/db10-0308 24. Crosignani A, Battezzati PM, Setchell KD, Invernizzi P, Covini G, Zuin M, Podda M. Tauroursodeoxycholic acid for treatment of primary biliary cirrhosis. A dose-response study. Dig Dis Sci. 1996 Apr;41(4):809-15. doi: 10.1007/BF02213140 25. Yanguas-Casás, N., Barreda-Manso, M. A., Nieto-Sampedro, M., & Romero-Ramírez, L. (2014). Tauroursodeoxycholic acid reduces glial cell activation in an animal model of acute neuroinflammation. Journal of neuroinflammation, 11, 50. https://doi.org/10.1186/1742-2094-11-50 26. Dionísio PA, Amaral JD, Ribeiro MF, Lo AC, D’Hooge R, Rodrigues CM. Amyloid-β pathology is attenuated by tauroursodeoxycholic acid treatment in APP/PS1 mice after disease onset. Neurobiol Aging. 2015 Jan;36(1):228-40. doi: 10.1016/j.neurobiolaging.2014.08.034 27. Lo AC, Callaerts-Vegh Z, Nunes AF, Rodrigues CM, D’Hooge R. Tauroursodeoxycholic acid (TUDCA) supplementation prevents cognitive impairment and amyloid deposition in APP/PS1 mice. Neurobiol Dis. 2013 Feb;50:21-9. doi: 10.1016/j.nbd.2012.09.003 28. Ramalho RM, Nunes AF, Dias RB, Amaral JD, Lo AC, D’Hooge R, Sebastião AM, Rodrigues CM. Tauroursodeoxycholic acid suppresses amyloid β-induced synaptic toxicity in vitro and in APP/PS1 mice. Neurobiol Aging. 2013 Feb;34(2):551-61. doi: 10.1016/j.neurobiolaging.2012.04.018 29. Rodrigues CM, Solá S, Brito MA, Brondino CD, Brites D, Moura JJ. Amyloid beta-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun. 2001 Feb 23;281(2):468-74. doi: 10.1006/bbrc.2001.4370 30. Ramalho RM, Borralho PM, Castro RE, Solá S, Steer CJ, Rodrigues CM. Tauroursodeoxycholic acid modulates p53-mediated apoptosis in Alzheimer’s disease mutant neuroblastoma cells. J Neurochem. 2006 Sep;98(5):1610-8. doi: 10.1111/j.1471-4159.2006.04007.x 31. Keene CD, Rodrigues CM, Eich T, Linehan-Stieers C, Abt A, Kren BT, Steer CJ, Low WC. A bile acid protects against motor and cognitive deficits and reduces striatal degeneration in the 3-nitropropionic acid model of Huntington’s disease. Exp Neurol. 2001 Oct;171(2):351-60. doi: 10.1006/exnr.2001.7755 32. Panella C, Ierardi E, De Marco MF, Barone M, Guglielmi FW, Polimeno L, Francavilla A. Does tauroursodeoxycholic acid (TUDCA) treatment increase hepatocyte proliferation in patients with chronic liver disease? Ital J Gastroenterol. 1995 Jun;27(5):256-8. 33. Chen W, Gluud C. Bile acids for liver-transplanted patients. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD005442. doi: 10.1002/14651858.CD005442. Update in: Cochrane Database Syst Rev. 2010;(3):CD005442. 34. Elia AE, Lalli S, Monsurrò MR, Sagnelli A, Taiello AC, Reggiori B, La Bella V, Tedeschi G, Albanese A. Tauroursodeoxycholic acid in the treatment of patients with amyotrophic lateral sclerosis. Eur J Neurol. 2016 Jan;23(1):45-52. doi: 10.1111/ene.12664. Epub 2015 Feb 9. Erratum in: Eur J Neurol. 2017 Apr;24(4):659.